
Opinion|Videos|August 1, 2024
Long-Term Impact of Bronchiectasis Exacerbations: Disease Progression, Patient Outcomes, and Economic Burden
Author(s)Panagis Galiatsatos, MD
An expert on bronchiectasis describes the extensive impact of exacerbations on patients’ lives and the health care system.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What is the long-term impact of bronchiectasis exacerbations on disease progression, patient morbidity, mortality, and quality of life?
- What is the economic impact of exacerbations on the healthcare system and on patients with bronchiectasis?
Advertisement
Related to this article

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.

This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.

The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
5



